TY - JOUR
T1 - Detection of α-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients
AU - Zehentner, Barbara K.
AU - Secrist, Heather
AU - Zhang, Xin Qun
AU - Hayes, Dawn C.
AU - Ostenson, Richard
AU - Goodman, Gary
AU - Xu, Jiangchun
AU - Kiviat, Mark
AU - Kiviat, Nancy
AU - Persing, David H.
AU - Houghton, Raymond L.
N1 - Funding Information:
We would like to thank Drs Mark Kiviat, Gary Goodman, Richard Osten-son, and Steve Loop for providing blood samples from prostate cancer patients and individuals with other urological disorders. We would also like to thank Andrew Lin for his assistance in facilitating sample and data transfer. This work was supported in part by grant R44 CA-80518 from the National Cancer Institute. The authors have no conflicts of interest that are directly relevant to the content of this study.
PY - 2006
Y1 - 2006
N2 - Background: α-Methylacyl-coenzyme-A racemase (AMACR) has been shown to be a highly specific marker for prostate cancer cells, even in the earliest stages of malignant progression. It is expressed at much higher levels than prostate-specific antigen (PSA) in malignant tissues, and is not expressed at appreciable levels in normal prostatic epithelium. In this study, we demonstrate the quantitative detection of AMACR transcripts in peripheral blood of prostate cancer patients using real-time RT-PCR. In addition, we have undertaken a pilot study to demonstrate the potential application of this technique for the detection of prostate tumor cells in urine samples from patients with prostate cancer. Methods: A real-time RT-PCR assay was developed for detection of the expression of AMACR in prostate cancer patients. Blood samples from 163 patients were tested at various stages of disease progression, with or without therapy. Blood specimens from patients with benign prostate disorders and other types of cancer were also evaluated. Results: In 28 of 58 samples from patients with known metastatic disease who were undergoing treatment, an AMACR expression signal above the cut-off value was detected, consistent with the presence of circulating tumor cells. In 39 of 88 patients with presumptive organ-confined disease, there was evidence of low levels of circulating tumor cells. Comparison of AMACR RT-PCR with known serum PSA values indicated that a combination of these parameters significantly increased the sensitivity for detection of progressive disease. In a pilot study analyzing urine samples from seven prostate cancer patients, elevated AMACR expression levels were detected in the urine sediments of four of six stage-T1 prostate cancer patients and in the one patient with stage-T2 prostate cancer. Conclusion: The data presented in this study indicates that AMACR real-time RT-PCR may aid in the detection and staging of prostate cancer.
AB - Background: α-Methylacyl-coenzyme-A racemase (AMACR) has been shown to be a highly specific marker for prostate cancer cells, even in the earliest stages of malignant progression. It is expressed at much higher levels than prostate-specific antigen (PSA) in malignant tissues, and is not expressed at appreciable levels in normal prostatic epithelium. In this study, we demonstrate the quantitative detection of AMACR transcripts in peripheral blood of prostate cancer patients using real-time RT-PCR. In addition, we have undertaken a pilot study to demonstrate the potential application of this technique for the detection of prostate tumor cells in urine samples from patients with prostate cancer. Methods: A real-time RT-PCR assay was developed for detection of the expression of AMACR in prostate cancer patients. Blood samples from 163 patients were tested at various stages of disease progression, with or without therapy. Blood specimens from patients with benign prostate disorders and other types of cancer were also evaluated. Results: In 28 of 58 samples from patients with known metastatic disease who were undergoing treatment, an AMACR expression signal above the cut-off value was detected, consistent with the presence of circulating tumor cells. In 39 of 88 patients with presumptive organ-confined disease, there was evidence of low levels of circulating tumor cells. Comparison of AMACR RT-PCR with known serum PSA values indicated that a combination of these parameters significantly increased the sensitivity for detection of progressive disease. In a pilot study analyzing urine samples from seven prostate cancer patients, elevated AMACR expression levels were detected in the urine sediments of four of six stage-T1 prostate cancer patients and in the one patient with stage-T2 prostate cancer. Conclusion: The data presented in this study indicates that AMACR real-time RT-PCR may aid in the detection and staging of prostate cancer.
UR - https://www.scopus.com/pages/publications/33845529343
U2 - 10.1007/BF03256217
DO - 10.1007/BF03256217
M3 - Article
C2 - 17154657
AN - SCOPUS:33845529343
SN - 1177-1062
VL - 10
SP - 397
EP - 403
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
IS - 6
ER -